Evidence map›Paper›PMID 39395266›Full record

ArticleESMO open2024

Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study.

D Xu, S Zeng, W Qiu, G Wang, Z Qin, Y Liu, S Zhou, Z Zhang, W Chang, Q Feng and 1 more

Erratum issued Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06202417 (Fruquintinib in Refractory Metastatic Colorectal Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06202417 completednot on this map

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

TypeobservationalSponsorFudan UniversityRan2021 to 2023Enrolled520ConditionsColorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal CancerArmsFruquintinib
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

D XuDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
S ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
W QiuDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
G WangDepartment of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Z QinDepartment of Oncology Center, Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Y LiuDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
S ZhouDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Z ZhangDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
W ChangDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Department of General Surgery, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China.
Q FengDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China.
J XuDepartment of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China. Electronic address: xujmin@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFruquintinib has been approved by the Food and Drug Administration for refractory metastatic colorectal cancer (mCRC). In clinical practice, fruquintinib is sometimes used in combination with other drugs, but its efficacy and safety are still unknown. In this study, we present a comprehensive analysis of the real-world treatment modalities involving fruquintinib in late-line settings for mCRC across six centers in China. PATIENTS AND

methodsPatients with refractory mCRC who received fruquintinib treatment in six centers in China between 1 January 2021 and 31 June 2022 were included in this study. Patients were categorized into two cohorts: the monotherapy group (treated solely with fruquintinib) and the combined group (received fruquintinib combined with chemotherapy and/or anti-programmed cell death protein 1 antibodies). Demographic, clinical, survival, and safety data were retrospectively analyzed. The study was registered at clinicaltrials.gov as NCT06202417.

resultsA total of 520 patients were included in this study. The median follow-up time was 9.7 months. The disease control rate was 64.8%. The median progression-free survival was 5.0 months and the median overall survival was 11.4 months. Of them, 387 (74.4%) were treated with fruquintinib alone, while 133 (25.6%) were administered fruquintinib plus chemotherapy and/or anti-programmed cell death protein 1 antibodies, respectively. Adverse events were reported by 91.3% (457/520) of patients. The rate of grade 3 or 4 toxicity was 42.4% (237/520). No treatment-related death occurred.

conclusionFruquintinib, either as a standalone treatment or in combination with other medications, demonstrates substantial efficacy and favorable tolerability in refractory mCRC patients.

Indexed as

BenzofuransColorectal NeoplasmsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChinaFemaleHumansMaleMiddle AgedNeoplasm MetastasisQuinazolinesRetrospective StudiesBenzofuransHMPL-013Quinazolineschemotherapycolorectal cancerfruquintinibimmune therapysalvage treatment

Identifiers

PMID39395266
PMCPMC11693424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.